You are now leaving the Torray Investment Partners website and being redirected to the Torray Fund website.
Selectivity and active management in the SMID-cap universe is key. For over 17 years, the Torray SMID Growth Strategy has, in general, outperformed over full-market cycles, experienced less dramatic drawdowns in stressful periods, and delivered an attractive risk-adjusted return stream.
Royalty Treatment. Royalty Pharma wants to benefit from the high-risk, high-return innovation in the pharmaceutical industry without bearing all the risks. Torray Investments' Shawn Hendon thinks the firm deserves more credit for doing that well.
For 25 Years, we have passionately believed a thoughtfully constructed, concentrated portfolio of businesses with attractive risk-adjusted growth characteristics can add value for clients over the long term.
Torray Investment Partners (“Torray”), an employee-owned investment advisor specializing in concentrated, low turnover growth- and value-oriented strategies, is proud to announce the reorganization of its flagship fund, The Torray Fund, (Ticker: TORYX) into The RBB Fund Trust (“RBB”).